No Data
Reported Earlier, Actinium To Present Improved Survival Outcomes In TP53 Positive Patients At The EHA 2024 and Long-Term Efficacy Results In Older Patients Receiving An Iomab-B Led Bone Marrow Transplant In The Phase 3 SIERRA Trial
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive I
Actinium : Iomab-B Phase 3 Trial Results Show Significant Survival Benefit In High-Risk AML Patients
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the...
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Rec
NYSE American New 52-Week Highs And Lows
New Highs 5 COMPANY SYMBOL HIGH VOLUME ------- ------ ---- ------ Actinium Pharmaceuticals ATNM 9.99 307,312 Am
Express News | Actinium Pharmaceuticals Inc : Stephens Initiates Coverage With Overweight Rating; Price Target $25
Actinium Pharmaceuticals Initiated at Overweight by Stephens & Co.
Actinium Pharmaceuticals Initiated at Overweight by Stephens & Co.